> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Cancels Panel Meeting for Tardive Dyskinesia Drug
- URL: https://www.fdaweb.com/fda-cancels-panel-meeting-for-tardive-dyskinesia-drug/
- Published: 2017-01-06T12:00:00.000Z
- Updated: 2026-09-14T21:58:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137657

FDA has canceled a 2/16-planned Psychopharmacologic Drugs Advisory Committee meeting to review a Neurocrine Biosciences NDA for Ingrezza (valbenazine) for treating tardive dyskinesia. FDA told Neurocrine that the priority review of the NDA is continuing as planned with a user fee target action date of 4/11, according to the company. The submission includes data from the Kinect 2 and Kinect 3 clinical trials along with the results from another 18 clinical trials. The agency granted a Breakthrough Therapy designation for the therapy in 2014.